Combined Effect of Angioinfarction with Immunotherapy in Patients with Stage IV Renal Cell Carcinoma.
10.3348/jkrs.1994.31.1.49
- Author:
Young Tae KO
;
Joo Hyeong OH
;
Yup YOON
;
Yu Mee JEONG
;
Sung Goo CHANG
- Publication Type:Original Article
- MeSH:
Carcinoma, Renal Cell*;
Catheters;
Ethanol;
Humans;
Immunotherapy*;
Interferon-alpha;
Survival Rate
- From:Journal of the Korean Radiological Society
1994;31(1):49-53
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To assess the combined effectiveness of angioinfarction and immunotherapy for improving survival in patients with stage IV renal cell carcinoma. MATERIALS AND METHODS:During the past 3 years, 13 patients of stage IV renal cell carcinoma were treated with angioinfarction and immunotherapy. Angioinfarction was performed on these 13 patients using absolute ethanol and occlusive baloon catheter. After angioinfarction, Interferon alpha was used for immunotherapy. For our analysis, 12 control patients of stage IV renal cell carcinoma without treatment were included in the study. Survival has been calculated according to the Kaplan and Meier method. RESULTS: The 1 year survival rate and median survival time in patients treated with angioinfarction and immunotherapy, were 46% and 13 months and in patients without treatment, 16% and 4 months, respectively. CONCLUSION:The combined treatment of angioinfarction and immunotherapy is of considerable value for improving survival in patients with stage IV renal cell carcinoma
